- Home
- OMAB vs DYN Comparison
OMAB vs DYN Comparison
Compare OMAB & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMAB | DYN |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.8B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OMAB | DYN |
|---|---|---|
| Price | $97.59 | $17.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $120.00 | $37.00 |
| AVG Volume (30 Days) | 67.1K | ★ 2.8M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.36 | N/A |
| Revenue Next Year | $13.05 | N/A |
| P/E Ratio | $21.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.69 | $11.92 |
| 52 Week High | $134.99 | $27.31 |
Technical Indicators
Market Signals| Indicator | OMAB | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 22.61 |
| Support Level | $96.55 | $16.55 |
| Resistance Level | $104.20 | $19.54 |
| Average True Range (ATR) | 2.47 | 1.14 |
| MACD | 0.07 | -0.64 |
| Stochastic Oscillator | 40.48 | 0.87 |
Price Performance
Historical ComparisonAbout OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates, maintains and develops airports in the Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages hotels, industrial parks, and individual airports. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, and in Others.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.